Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation

Abstract We retrospectively reviewed 292 patients who received a second line of therapy post ASCT for their light chain amyloidosis. Most patients (40%) were treated with an alkylator + PI ± dex or PI ± dex followed by an alkylator + 2nd-gen IMiD ± dex or 2nd-gen IMiD ± dex (26%), an alkylator ± ste...

Full description

Bibliographic Details
Main Authors: Abdullah S. Al Saleh, Mohammad S. Ebraheem, M. Hasib Sidiqi, Angela Dispenzieri, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, David Dingli, Wilson I. Gonsalves, Taxiarchis V. Kourelis, William J. Hogan, Suzanne R. Hayman, Prashant Kapoor, Shaji K. Kumar, Morie A. Gertz
Format: Article
Language:English
Published: Nature Publishing Group 2022-04-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00655-z

Internet

https://doi.org/10.1038/s41408-022-00655-z

Similar Items